Reckitt Benckiser: Morgan Stanley sees near-term upside risk
(CercleFinance.com) - Analysts at Morgan Stanley point to potential near-term upside risks for Reckitt Benckiser after the British consumer goods maker's material underperformance versus all major indices and large-cap peers over the past 18 months.
In a research report to clients, the broker - which maintains an "overweight" rating on the stock, with a target price of 9,000 pence - said the maker of Nurofen and Strepsils could get a boost to its sales from the flu season.
Committed to its bullish long-term view, Morgan Stanley believes that Reckitt should trade broadly in line with the valuations for best-in-class operators, such as Colgate by 2020.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
In a research report to clients, the broker - which maintains an "overweight" rating on the stock, with a target price of 9,000 pence - said the maker of Nurofen and Strepsils could get a boost to its sales from the flu season.
Committed to its bullish long-term view, Morgan Stanley believes that Reckitt should trade broadly in line with the valuations for best-in-class operators, such as Colgate by 2020.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.